Search

everythinglearnresearchcommunity

for

Search:↓

Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Fucoidan may help regrow hair and reduce inflammation in hair loss.

Finasteride may help reduce tic severity in male Tourette syndrome patients.

New compounds may help treat prostate issues without affecting androgen receptors.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.

Genetic differences affect breast cancer treatment success with tamoxifen in South African patients.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Finasteride use linked to increased risk of sexual dysfunction, especially in younger people.

Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.

Testosterone undecanoate can reduce the negative effects of Finasteride on male reproductive health.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Early diagnosis of frontal fibrosing alopecia is crucial to prevent permanent hair loss.

A new compound shows promise as a topical treatment for hair loss.

HST and HST/F promote hair growth and may help treat alopecia.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

New compounds with carborane showed anti-androgen effects similar to flutamide.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

A microemulsion with Carthamus tinctorius extract effectively inhibits 5α-reductase and improves skin and hair follicle delivery.

Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.

The new finasteride delivery system using chitosan-based nanoniosomes shows promise for prostate cancer prevention.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.

Formyl-peptide receptor agonists could be new anti-inflammatory drugs.

Antiretrovirals can affect finasteride's effectiveness, so dose adjustments may be needed for men on HIV treatment.

Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.